Multibagger Healthcare Stock – Indraprastha Medical Corporation
Anand Rathi Remains Positive on the Multibagger Healthcare Stock Indraprastha Medical Corporation, Mainting it as a Top Pick, and Expects about 40% UPSIDE to the Target Price of the Target Price of 590.
The Indraprastha Medical Corporation Share Price Has Risen more than 69% in a year. While it has grown almost 4-fold in the last two years. The Indraprastha Medical Corporation Share Price is up almost 613% in the last 5 years and has given multibagger returns to the investors.
Key triggers for more UPSIDE in the Multibagger Healthcare Stock – Indraprastha Medical Corporation
The primary re-rating trigger, as per anand rathi research, is the delhi government’s stake sale expertation in the company
As per anand rathi, referring to their interaction with the management, they say that it was revealed that the promoters are negotiating to purchase all or a portion of the delhi government’s 26% stake, who have stake, who is the right. Hold.
Although the timeline is uncertain, as per anand rathi research, they think that if the deal proceeds, it will create more Room for Room for Expantion in Both Emerging and Existing Regents, Including the ncr.
Indraprastha is expanding its bed capacity from the present 802 beds. The expansions at its current location in Sarita Vihar (Delhi) Are in Accordance with the Industry’s Expansion of Bed Capacity, with 350 beds anticipated to be added by added by
The projected cost of this is 580 Crore. About 40% of the project’s cost is anticipated to be spent in fy26, with the remouting Amount Falling in FY27 and FY28.
Being the corporation is Spending about Rs1.8 billion to create two underground floors for parking (about 1,300 automobiles and 350+ two-wHELERS), The Cost Per Bed Is Greatr for this Site. The goal is to increase the number of beds to approximately
Anand Rathi Research Says That, Further, With the New Government Coming in, Delhi Should Augur Well for the Company as it can expert the promoters (can be an option Value). They have broadly maintained their Estimates for FY26 and FY27.
Disclaimer: The views and recommendations made about individual analysts or broking companies and not of mint. We Advise Investors to Check With Certified Experts Before Making Any Investments Decisions.
Discover more from gautamkalal.com
Subscribe to get the latest posts sent to your email.
Be First to Comment